Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for

Treatment of Coronary Artery Disease

ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.

"XIENCE V represents an important treatment advance for the estimated 13 million people in the United States suffering from coronary artery disease, and we believe XIENCE V will quickly become the new standard for drug eluting stents given its outstanding clinical results," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Physicians in the United States have been waiting for years to treat their patients with a technology that delivers on the promise of drug eluting stents through both ease of use and excellent clinical performance, and XIENCE V is that technology."

The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Coronary artery disease occurs when plaque build- up narrows the arteries and reduces blood flow to the heart, which can lead to chest pain or a heart attack.

"XIENCE V was designed to improve safety and efficacy compared to earlier generation stents. The long-term clinical data from two studies performed in both the United States and Europe have now confirmed that XIENCE V is a true next-generation drug elu
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 North Carolina-based life ... M.D., Professor of Medicine, Mayo Clinic College of ... of Directors. , Entegrion’s Executive Chairman ... to have Dr. Noel, a distinguished physician and ... join Entegrion’s Board. His expertise in hematology and ...
(Date:3/5/2015)... March 5, 2015  UBM Medica US announces ... leading online community to help oncologists and other ... information available regarding the use of targeted therapies ... March is National Kidney Cancer ... effective adjuvant treatment options for renal cell carcinoma ...
(Date:3/5/2015)...  In response to the incorrect assertions by LD, ... on February 12, 2015. Impeto Medical SAS and ... and their SUDOSCAN® devices have been proven to provide ... to have the courts decide this dispute rather than ... articles written by Key Opinion Leaders, published by significant ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3
... SAN FRANCISCO, Sept. 3 Osprey Pharmaceuticals ... protein therapeutics,that selectively target chemokine-activated leukocytes that ... announced today that,the company has raised $11 ... capital,funding. The financing was led by Burrill ...
... NANJING, China, Sept. 3 ,Acesys Pharmatech and Provid ... discovery expertise and project management,capabilities of Provid in ... cost structure of Acesys in China., The ... all,aspects of medicinal chemistry for clients in the ...
... TUSTIN, Calif., Sept. 3 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... results for the first quarter of fiscal year 2009 ... host a conference call and,webcast to discuss the results ... Peregrine,s senior management will discuss financial results for the,first ...
Cached Biology Technology:Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing 2Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing 3Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results 2
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... , Jan. 28, 2015 Research and Markets ... addition of the "Global Biometrics Market (2014-2020): ... and Countries " report to their offering. ... Asia-Pacific is anticipated to overtake ... owing to increasing government spending towards IT security, ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... malaria, TB & HIV/AIDS cause more than five million deaths ... of Washington and represent one of the world,s major ... of the 21st century. In the May 26, 2011, edition ... Director Alan Aderem, Ph.D., along with Rino Rappuoli, Ph.D., Global ...
... MASS.One helpful action anyone can take in response to ... Trees and plants capture carbon dioxide during photosynthesis, thereby ... and storing some of it in their woody tissue. ... of trees to store carbon by altering forest nitrogen ...
... Species Exploration at Arizona State University and a committee ... for the top 10 new species described in 2010. ... a pancake batfish recently discovered by Prosanta Chakrabarty, curator ... colleagues. Halieutichthys intermedius , more commonly referred to ...
Cached Biology News:2020 vision of vaccines for malaria, TB and HIV/AIDS 2Global warming may affect the capacity of trees to store carbon, MBL study finds 2Fish species discovered by LSU researcher makes 2011 top 10 list 2
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
... Researchers no longer need to perform time consuming ... With Mutation Surveyor, any found variants of the ... clearly indicated in our mutation electropherogram as a ... the bi-directional analysis mode is over 99%, with ...
... 220-240 V, is used for biolistic particle delivery ... an adjustable helium pulse to sweep DNA-, RNA-, ... wall of a small plastic cartridge directly into ... in situ, in vitro, in vivo, and ex ...
Biology Products: